retatrutide for diabetes type 2 phase 2 results 2024 ada trial demonstrate benefits of in obesity, diabetes, NASH Efficacy and Safety of Retatrutide – Retatrutide Phase 2: Type 2

Treatment of mice with DS-induced colitis (resembling human ulcerative colitis) with the human GLP-2 analog h(Gly 2 )GLP, twice daily for 10 days, reverses weight loss independent on food intake, decreases interleukin-1 expression and increased colon length, crypt depth, and mucosal area compared to treatment with saline (Drucker et al., 1999)

retatrutide is accessible only via approved trials, and tesamorelin use would constitute unlicensed importation in most practical scenarios

These testimonials reflect personal experiences and should not be considered typical results or medical evidence

Standards of care and common application practices for GLP-1 peptides

Rising incidence of obesity and related conditions is driving the GLP-1 industry growth

2022;17(3):e0264974